Yebio Bioengineering Co., Ltd. of Qingdao is a leading Chinese veterinary biological product manufacturer, specializing in the research, development, production, and global distribution of vaccines and diagnostic reagents for livestock and companion animals. As a subsidiary of China Animal Husbandry Industry Co., Ltd., Yebio operates with a strategic mission to safeguard animal health and contribute to global biosecurity through innovation and scientific rigor.
Core Business and Product Portfolio
Yebio's product line spans a broad spectrum of veterinary biologicals, with a strong emphasis on vaccines for poultry, swine, and companion animals. The company develops both inactivated and live vaccines, as well as diagnostic reagents tailored for disease prevention and monitoring in modern animal husbandry.
Poultry Vaccines
- Recombinant Avian Influenza Virus (H5+H7) Trivalent Inactivated Vaccine
- Newcastle Disease and Avian Influenza (H9 Subtype) Bivalent Inactivated Vaccine
- Infectious Bronchitis Live Vaccine
- Egg Drop Syndrome Inactivated Vaccine
Duck Vaccines
- Duck Tembusu Virus Disease Live Vaccine
- Duck Viral Hepatitis Bivalent Yolk Antibody
Swine Vaccines
- Swine Fever Gene Engineering Subunit Vaccine
- Porcine Circovirus Type 2 Gene Engineering Subunit Vaccine
- Pseudorabies Inactivated Vaccine
Companion Animal Vaccines
- Rabies Inactivated Vaccine
Diagnostic Reagents
- Test kits for avian influenza, swine fever, and other infectious diseases used in veterinary laboratories and quarantine facilities.
Specialization and R&D Capabilities
Yebio is highly regarded for its R&D capabilities, employing over 200 scientific researchers across various disciplines, including molecular biology, virology, and immunology. The company operates:
- Three national-level research platforms
- Two postdoctoral research stations
- More than 30 patented technologies
Its vaccine development programs are backed by partnerships with leading agricultural universities and national key laboratories in China. Yebio has played a pivotal role in the innovation of recombinant avian influenza vaccines, one of the few manufacturers with MOA-approved multivalent recombinant formulations.
Production Infrastructure
Yebio's production capabilities are robust, featuring:
- Over 100,000 square meters of GMP-certified manufacturing space
- 8 vaccine production lines (both bacterial and viral)
- Annual capacity exceeding 10 billion doses
- Fully automated filling and packaging lines ensuring high sterility and accuracy
The company adheres to OIE and GMP guidelines, ensuring products meet international quality standards suitable for export.
Global Presence and Export Markets
Yebio exports to more than 30 countries across Asia, Africa, South America, and the Middle East, including:
- Egypt
- Bangladesh
- Pakistan
- Vietnam
- Nigeria
- Kenya
It has obtained multiple product registrations abroad and collaborates with government veterinary departments and private distributors in its key markets. Shipment records from platforms like ImportYeti and Volza confirm regular bulk vaccine shipments to Africa and South Asia over the past 5 years.
Certifications and Compliance
- GMP Certification for Veterinary Biological Products by the Ministry of Agriculture
- ISO 9001: Quality Management Systems
- ISO 14001: Environmental Management Systems
- Approved supplier for FAO and OIE-coordinated programs
- Ongoing WHO-PQ alignment for select vaccine lines
Financial and Operational Strength
Yebio is backed by China National Agricultural Development Group Co., Ltd., a key player in China’s state-owned agribusiness sector. As part of this vertically integrated group, Yebio enjoys financial stability and government-supported R&D infrastructure. The company's vaccine sales have consistently ranked among the top in China's veterinary biologics sector, with estimated annual revenue surpassing RMB 1 billion (approx. USD 140 million).
Strategic Partnerships and Recognition
- Nationally designated enterprise for avian influenza prevention and control
- Collaborative development projects with Chinese Academy of Agricultural Sciences
- Recipient of multiple provincial and national innovation awards
- Key supplier during government campaigns to eradicate HPAI and classical swine fever
Yebio Bioengineering Co., Ltd. continues to lead China’s animal vaccine industry with innovation, international collaboration, and a deep commitment to animal health and global disease prevention. Its combination of scale, scientific depth, and regulatory compliance makes it a trusted partner for governments, integrators, and veterinary distributors worldwide.
